APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
NCT00343460
Completed
This randomized phase III trial is studying APF530 and dexamethasone to see how well they work compared with palonosetron and dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
02/10/2017
Locations: Pasco Pinellas Cancer Center - New Port Richey, New Port Richey, Florida +1 locations
Conditions: Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma
NCT00560352
Terminated
The purpose of this study is to determine the safety and tolerability of dasatinib with bortezomib in the treatment of relapsed or refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2017
Locations: Orlando Health, Inc. M.D. Anderson Cancer Center Orlando, Orlando, Florida
Conditions: Multiple Myeloma
Register for Updates
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
NCT00806819
Completed
The trial will be performed to evaluate if BIBF 1120 in combination with standard pemetrexed therapy is more effective than placebo (inactive capsule) plus standard pemetrexed therapy in patients with stage IIIB, IV or recurrent NSCLC. Safety information about BIBF1120/pemetrexed will be obtained.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/08/2016
Locations: Boehringer Ingelheim Investigational Site, Aventura, Florida +6 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
NCT00005601
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining combination chemotherapy with monoclonal antibody therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus rituximab in treating patients who h... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2016
Locations: Mayo Clinic, Jacksonville, Florida
Conditions: Lymphoma
Register for Updates
Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492
NCT02150213
Completed
To provide medical follow-up to patients exposed to BGG492 for more than 28 days in study CBGG492A2207 (NCT 01147003) and/or CBGG492A2212 (NCT 01338805).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2016
Locations: Novartis Investigative Site, Tallahassee, Florida
Conditions: Adrenocortical Adenoma, Endometrial Stromal Sarcomas
Register for Updates
A Bioequivalence Study of Two Ciprofloxacin/Dexamethasone Formulations in Patients With Otitis Externa
NCT01910155
Terminated
The objective of this study is to compare the relative efficacy and safety of the test formulation of ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension (Par Pharmaceutical Companies, Inc.) to the already-marketed formulation CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%) sterile otic suspension (Alcon) in the treatment of acute bacterial otitis externa.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/14/2016
Locations: ENT of South Florida, Boyton Beach, Florida +6 locations
Conditions: Otitis Externa
Register for Updates
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
NCT01188187
Completed
This Phase 3 study has been designed to confirm that adding custirsen to standard first-line docetaxel/prednisone treatment can slow tumor progression and enhance survival outcomes compared to standard first-line docetaxel/prednisone treatment alone. This will be a randomized, open-label, multicenter, international trial. Treatment will consist of docetaxel/prednisone/custirsen vs. docetaxel/prednisone. A total of at least 1000 patients will be randomized. Patients will be randomly assigned with... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/13/2016
Locations: Teva Investigational Site 106, Fort Myers, Florida +1 locations
Conditions: Prostate Cancer
Register for Updates
Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy
NCT00880191
Completed
RATIONALE: Gabapentin may prevent or reduce delayed nausea and vomiting caused by chemotherapy. It is not yet known whether gabapentin is more effective than a placebo in preventing nausea and vomiting. PURPOSE: This randomized phase III trial is studying the side effects of gabapentin and to see how well it works compared with a placebo in preventing nausea and vomiting in patients receiving chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2016
Locations: Mayo Clinic - Jacksonville, Jacksonville, Florida
Conditions: Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Radiation Therapy and High-Dose Corticosteroids in Treating Older Patients With Primary CNS Non-Hodgkin's Lymphoma
NCT00003278
Completed
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with a corticosteroid, such as dexamethasone, may be an effective treatment for non-Hodgkin's lymphoma. PURPOSE: Phase II trial to study the effectiveness of radiation therapy and high-dose dexamethasone in treating older patients with primary CNS non-Hodgkin's lymphoma.
Gender:
ALL
Ages:
70 years and above
Trial Updated:
07/01/2016
Locations: Mayo Clinic, Jacksonville, Florida
Conditions: Lymphoma
Register for Updates
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
NCT00002494
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and alternating regimens of chemotherapy in treating patients who have non-Hodgkin's lymphoma or acute lymphocytic leukemia.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
06/30/2016
Locations: CCOP - Mount Sinai Medical Center, Miami Beach, Florida
Conditions: Leukemia, Lymphoma
Register for Updates
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
NCT01522872
Unknown
This phase 2 study is designed to evaluate the safety and tolerability activity of TH-302 and dexamethasone with or without bortezomib or pomalidomide in subjects with relapsed/refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2016
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Multiple Myeloma
Register for Updates
Iontophoresis Delivery of Dexamethasone Phosphate for Non-infectious, Non-necrotizing Anterior Scleritis, Phase 1 Dose-varying Study
NCT01059955
Completed
This is an initial clinical trial evaluating whether different doses of iontophoresis for delivery of dexamethasone phosphate can be tolerated by eyes of patients with non-infections, non-necrotizing scleritis. A secondary goal is to get preliminary information about whether the treatment is likely to be an effective treatment for scleritis. If the results are favorable, further trials evaluating the treatment may be pursued. Funding sources: FDA OOPD, Eyegate Pharmaceuticals, Inc.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/20/2016
Locations: University of Miami, Miami, Florida
Conditions: Non-infectious, Non-necrotizing Anterior Scleritis
Register for Updates